University of California, San Francisco, and private practice Los Altos, CA.
Asia Pac J Ophthalmol (Phila). 2019 Nov-Dec;8(6):432-435. doi: 10.1097/APO.0000000000000266.
The light-adjustable lens is the first Food and Drug Administration (FDA)-approved product from an entirely new category of intraocular lenses (IOLs). The 3-piece foldable silicone light-adjustable lens is implanted through a small incision after phacoemulsification. A slit-lamp-based digital light delivery device is used to adjust and then lock-in the IOL power during the first postoperative month. Up to 4.5 diopters (D) of cylindrical or spherical adjustment can be achieved. This should offer significant advantages in difficult IOL power calculation cases, such as postrefractive eyes. In addition to achieving better refractive accuracy, an adjustable IOL will now allow patients to test and elect a different refractive target postoperatively. This paradigm shift will change how cataract patients choose their refractive objectives, and how ophthalmologists will be able to achieve them. For example, adjustable IOLs may increase the popularity of pseudophakic monovision and bilateral same-day sequential surgery. For those electing adjustable IOL, preoperative patient counseling will change and certain pre- and intraoperative technologies, such as intraoperative aberrometry and digital astigmatic axis marking, would become superfluous.
光调节型人工晶状体是首个获得美国食品药品监督管理局（FDA）批准的全新类别人工晶状体（IOL）产品。该 3 件式折叠式硅胶光调节型人工晶状体在超声乳化术后通过小切口植入。术后第一个月，使用基于裂隙灯的数字光传输设备来调节并锁定 IOL 度数。最大可实现 4.5 屈光度（D）的圆柱镜或球镜调节。这在计算困难的 IOL 度数的情况下（例如屈光性眼）具有明显的优势。除了实现更好的屈光准确性外，可调节人工晶状体现在还可以让患者在术后测试和选择不同的屈光目标。这种范式转变将改变白内障患者选择其屈光目标的方式，以及眼科医生实现这些目标的方式。例如，可调节人工晶状体可能会增加无晶状体单眼视和双眼同日序贯手术的普及。对于选择可调节人工晶状体的患者，术前患者咨询将发生变化，某些术前和术中技术（如术中像差测量和数字散光轴向标记）将变得多余。
